

Listing of patient Demographics, Characteristics, and Cardiovascular Risks

Page 1 of 16

At Baseline

17:15 22JAN2009

Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
101	1001	Dula_1.5	63.0	Male	UK	6.0	10.30
58.0	155.0	24.1					
	1002	Placebo	78.0	Female	UK	8.0	7.60
51.0	155.0	21.2					
	1003	Placebo	24.0	Female	UK	24.0	10.30
67.0	155.0	27.9					
	1004	Placebo	18.0	Female	UK	24.0	10.20
90.0	154.0	37.9					
	1006	Placebo	36.0	Female	UK	7.0	4.60
87.0	156.0	35.7					
	1007	Dula_1.5	75.0	Male	UK	9.0	4.70
57.0	155.0	23.7					
	1008	Placebo	83.0	Female	UK	5.0	.
59.0	155.0	24.6					
	1010	Dula_0.75	31.0	Male	UK	11.0	5.30
87.0	155.0	36.2					
	1011	Placebo	53.0	Female	UK	22.0	10.40
90.0	155.0	37.5					
	1012	Dula_1.5	18.0	Male	UK	17.0	5.10
95.0	155.0	39.5					
	1013	Placebo	28.0	Female	UK	7.0	10.10
92.0	155.0	38.3					
	1014	Dula_1.5	29.0	Male	UK	37.0	5.20
63.0	155.0	26.2					
	1015	Dula_1.5	85.0	Male	UK	20.0	10.50
94.0	151.0	41.2					
	1016	Dula_0.75	37.0	Male	UK	18.0	7.50
62.0	155.0	25.8					
	1017	Placebo	78.0	Female	UK	9.0	5.40
77.0	174.0	25.4					
	1018	Dula_0.75	56.0	Male	UK	11.0	11.90
55.0	180.0	17.0					
	1019	Placebo	71.0	Female	UK	17.0	11.30
.	155.0						
	1020	Placebo	69.0	Female	UK	34.0	4.90
91.0	155.0	37.9					
102	1021	Dula_1.5	40.0	Male	KR	25.0	6.60
49.0	155.0	20.4					
	1023	Placebo	76.0	Female	KR	6.0	11.80
72.0	155.0	30.0					
	1025	Placebo	52.0	Female	KR	15.0	12.10
56.0	155.0	23.3					
	1026	Dula_1.5	73.0	Male	KR	28.0	5.60
62.0	155.0	25.8					
	1027	Dula_1.5	18.0	Male	KR	35.0	13.10
102.0	155.0	42.5					
	1028	Dula_0.75	59.0	Male	KR	18.0	4.10
70.0	155.0	29.1					
	1029	Dula_0.75	83.0	Female	KR	27.0	.
87.0	155.0	36.2					
	1030	Dula_1.5	85.0	Male	KR	33.0	4.10
74.0	155.0	30.8					
	1031	Dula_0.75	25.0	Male	KR	20.0	7.80
97.0	155.0	40.4					
	1032	Placebo	56.0	Female	KR	11.0	10.60

95.0	155.0	39.5						
	103	1033	Placebo	63.0	Female	US	14.0	6.30
76.0	181.0	23.2						
		1034	Dula_1.5	65.0	Male	US	23.0	10.30
51.0	155.0	21.2						
		1035	Placebo	36.0	Female	US	28.0	4.60
65.0	155.0	27.1						
		1036	Placebo	52.0	Female	US	37.0	11.30
51.0	155.0	21.2						
		1037	Placebo	81.0	Female	US	36.0	9.30
54.0	155.0	22.5						
		1038	Dula_1.5	22.0	Male	US	29.0	9.80
79.0	178.0	24.9						
		1039	Placebo	68.0	Female	US	16.0	3.90
74.0	155.0	30.8						

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 2 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
103	1040	Dula_0.75	21.0	Male	US	29.0	2.30
56.0	155.0	23.3					
	1042	Placebo	54.0	Female	US	13.0	8.90
71.0	155.0	29.6					
	1043	Placebo	57.0	Female	US	38.0	3.10
85.0	155.0	35.4					
	1044	Placebo	40.0	Female	US	8.0	8.50
68.0	155.0	28.3					
	1045	Dula_1.5	53.0	Male	US	12.0	8.30
88.0	155.0	36.6					
	1046	Placebo	53.0	Female	US	10.0	7.50
88.0	155.0	36.6					
	1047	Dula_0.75	84.0	Female	US	15.0	7.40
60.0	155.0	25.0					
	1048	Placebo	42.0	Female	US	12.0	3.80
95.0	155.0	39.5					
	1050	Dula_1.5	37.0	Male	US	21.0	10.00
90.0	167.0	32.3					
	1051	Dula_0.75	76.0	Male	US	33.0	8.60
54.0	167.0	19.4					
	1052	Placebo	68.0	Female	US	14.0	11.90
55.0	167.0	19.7					
	1053	Dula_0.75	53.0	Male	US	12.0	10.40
63.0	167.0	22.6					
	1054	Dula_1.5	18.0	Male	US	13.0	9.70
95.0	167.0	34.1					
	1055	Placebo	18.0	Female	US	23.0	4.50
88.0	167.0	31.6					
	1057	Dula_1.5	18.0	Male	US	37.0	10.60
55.0	167.0	19.7					
	1058	Placebo	86.0	Female	US	17.0	7.90
46.0	167.0	16.5					
	1059	Placebo	56.0	Female	US	22.0	3.20
71.0	167.0	25.5					
	1060	Dula_1.5	64.0	Male	US	14.0	7.70
79.0	167.0	28.3					
	1061	Dula_0.75	23.0	Male	US	14.0	2.20
74.0	167.0	26.5					
	1062	Placebo	18.0	Female	US	30.0	4.20
45.0	167.0	16.1					
104	1063	Dula_1.5	41.0	Male	MX	29.0	3.00
67.0	167.0	24.0					
	1064	Dula_1.5	86.0	Male	MX	13.0	6.90
55.0	167.0	19.7					
	1065	Placebo	45.0	Female	MX	13.0	9.30
56.0	167.0	20.1					
	1066	Dula_1.5	75.0	Male	MX	12.0	4.80
80.0	167.0	28.7					
	1067	Placebo	85.0	Female	MX	4.0	12.10
97.0	181.0	29.6					
	1068	Dula_0.75	34.0	Male	MX	28.0	7.90
81.0	178.0	25.6					
	1069	Dula_1.5	52.0	Male	MX	24.0	2.50
97.0	167.0	34.8					
	1070	Dula_0.75	30.0	Male	MX	29.0	3.80

91.0	167.0	32.6					
	1071	Dula_0.75	65.0	Male	MX	6.0	4.60
58.0	167.0	20.8					
	1072	Dula_1.5	62.0	Male	MX	24.0	12.90
87.0	167.0	31.2					
	1073	Dula_0.75	77.0	Female	MX	18.0	4.60
57.0	167.0	20.4					
	1074	Dula_1.5	18.0	Male	MX	15.0	9.70
95.0	167.0	34.1					
	1075	Dula_1.5	81.0	Male	MX	17.0	10.50
53.0	167.0	19.0					
	1076	Dula_0.75	34.0	Male	MX	15.0	12.80
92.0	167.0	33.0					
	1077	Dula_0.75	72.0	Male	MX	30.0	8.30
76.0	167.0	27.3					
	1078	Dula_1.5	49.0	Male	MX	30.0	5.90
49.0	179.0	15.3					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 3 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
105	1079	Placebo	68.0	Female	IN	20.0	6.90
69.0	167.0	24.7					
	1080	Placebo	23.0	Female	IN	7.0	13.00
76.0	172.0	25.7					
	1082	Dula_0.75	18.0	Male	IN	38.0	8.80
55.0	167.0	19.7					
	1083	Dula_0.75	61.0	Male	IN	9.0	7.80
82.0	167.0	29.4					
	1084	Placebo	28.0	Female	IN	31.0	4.90
50.0	179.0	15.6					
	1085	Dula_1.5	38.0	Male	IN	23.0	7.30
66.0	167.0	23.7					
	1086	Dula_1.5	18.0	Male	IN	5.0	10.90
54.0	167.0	19.4					
	1087	Dula_0.75	18.0	Female	IN	18.0	11.70
98.0	165.0	36.0					
	1088	Placebo	29.0	Female	IN	14.0	10.90
60.0	167.0	21.5					
	1090	Dula_1.5	36.0	Male	IN	7.0	3.70
75.0	175.0	24.5					
106	1091	Dula_1.5	30.0	Male	IN	14.0	4.50
57.0	175.0	18.6					
	1092	Dula_0.75	52.0	Female	IN	32.0	6.30
72.0	175.0	23.5					
	1093	Placebo	49.0	Female	IN	20.0	6.90
62.0	175.0	20.2					
	1094	Placebo	45.0	Female	IN	7.0	8.20
99.0	175.0	32.3					
	1095	Placebo	83.0	Female	IN	13.0	10.00
88.0	175.0	28.7					
	1096	Placebo	46.0	Female	IN	9.0	9.50
92.0	175.0	30.0					
	1097	Dula_1.5	80.0	Male	IN	25.0	2.90
77.0	175.0	25.1					
	1098	Dula_1.5	49.0	Male	IN	23.0	3.40
45.0	175.0	14.7					
	1099	Dula_1.5	32.0	Male	IN	4.0	5.30
79.0	175.0	25.8					
	1100	Dula_1.5	80.0	Male	IN	5.0	3.80
91.0	175.0	29.7					
	1101	Dula_1.5	48.0	Male	IN	5.0	9.20
81.0	175.0	26.4					
	1102	Placebo	86.0	Female	IN	36.0	7.20
70.0	175.0	22.9					
	1103	Dula_1.5	20.0	Male	IN	11.0	5.70
53.0	175.0	17.3					
	1104	Dula_0.75	18.0	Male	IN	16.0	7.90
66.0	175.0	21.6					
	1105	Placebo	18.0	Female	IN	5.0	9.40
58.0	175.0	18.9					
	1106	Placebo	65.0	Female	IN	32.0	11.50
87.0	160.0	34.0					
	1107	Dula_0.75	37.0	Male	IN	8.0	9.90
77.0	175.0	25.1					
	1108	Dula_0.75	74.0	Male	IN	20.0	5.10

83.0	158.0	33.2					
	1109	Dula_0.75	41.0	Female	IN	19.0	10.30
48.0	158.0	19.2					
	1110	Placebo	18.0	Female	IN	26.0	3.90
94.0	158.0	37.7					
	1111	Dula_1.5	41.0	Male	IN	17.0	6.20
57.0	158.0	22.8					
	1112	Dula_0.75	23.0	Male	IN	6.0	11.70
49.0	158.0	19.6					
	1113	Placebo	73.0	Female	IN	28.0	7.20
73.0	158.0	29.2					
	1115	Dula_1.5	59.0	Male	IN	21.0	4.90
60.0	158.0	24.0					
	1116	Dula_1.5	85.0	Male	IN	28.0	6.40
97.0	161.0	37.4					
	1117	Dula_0.75	38.0	Male	IN	35.0	2.60
65.0	158.0	26.0					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 4 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
106	1118	Dula_1.5	21.0	Male	IN	36.0	12.40
78.0	158.0	31.2					
	1119	Dula_1.5	33.0	Male	IN	35.0	9.50
75.0	158.0	30.0					
	1120	Dula_1.5	43.0	Male	IN	15.0	6.10
54.0	158.0	21.6					
	1122	Dula_1.5	78.0	Male	IN	25.0	5.30
99.0	158.0	39.7					
	1123	Dula_1.5	86.0	Male	IN	30.0	6.70
69.0	158.0	27.6					
	1124	Dula_1.5	85.0	Male	IN	12.0	.
72.0	156.0	29.6					
107	1125	Dula_1.5	40.0	Male	CN	26.0	8.90
83.0	158.0	33.2					
	1126	Dula_1.5	67.0	Male	CN	8.0	8.60
100.0	158.0	40.1					
	1127	Placebo	18.0	Female	CN	18.0	9.60
86.0	158.0	34.4					
	1128	Placebo	19.0	Female	CN	32.0	11.80
86.0	158.0	34.4					
	1129	Placebo	47.0	Female	CN	15.0	3.90
63.0	158.0	25.2					
	1130	Dula_0.75	84.0	Female	CN	17.0	9.60
64.0	158.0	25.6					
	1131	Dula_0.75	18.0	Male	CN	20.0	9.70
88.0	153.0	37.6					
	1132	Dula_0.75	78.0	Male	CN	36.0	10.00
63.0	158.0	25.2					
	1133	Dula_1.5	44.0	Male	CN	22.0	9.10
70.0	158.0	28.0					
	1134	Dula_0.75	67.0	Male	CN	33.0	.
70.0	158.0	28.0					
	1135	Dula_1.5	52.0	Male	CN	21.0	6.20
68.0	169.0	23.8					
	1136	Placebo	19.0	Female	CN	8.0	10.30
73.0	158.0	29.2					
	1137	Placebo	40.0	Female	CN	22.0	12.30
69.0	158.0	27.6					
	1138	Dula_1.5	47.0	Male	CN	7.0	11.90
59.0	158.0	23.6					
	1139	Dula_1.5	43.0	Male	CN	17.0	12.20
55.0	164.0	20.4					
	1140	Placebo	31.0	Female	CN	8.0	3.90
85.0	158.0	34.0					
	1141	Placebo	27.0	Female	CN	12.0	12.80
78.0	158.0	31.2					
	1142	Dula_0.75	32.0	Male	CN	30.0	4.10
102.0	158.0	40.9					
	1143	Placebo	85.0	Female	CN	36.0	6.60
72.0	158.0	28.8					
	1144	Dula_0.75	27.0	Male	CN	35.0	8.20
62.0	158.0	24.8					
	1145	Placebo	44.0	Female	CN	10.0	2.40
49.0	158.0	19.6					
	1146	Dula_1.5	82.0	Male	CN	5.0	11.30

54.0	158.0	21.6					
	1147	Placebo	25.0	Female	CN	17.0	5.00
94.0	158.0	37.7					
	1148	Dula_0.75	23.0	Male	CN	26.0	8.30
49.0	158.0	19.6					
	1149	Dula_0.75	46.0	Male	CN	27.0	8.00
54.0	174.0	17.8					
	1150	Dula_1.5	35.0	Male	CN	31.0	2.60
81.0	158.0	32.4					
	1151	Placebo	32.0	Female	CN	15.0	9.10
69.0	158.0	27.6					
	1152	Dula_0.75	23.0	Male	CN	20.0	5.60
47.0	158.0	18.8					
	1154	Dula_1.5	29.0	Male	CN	5.0	9.70
50.0	158.0	20.0					
	1155	Placebo	73.0	Female	CN	27.0	4.70
63.0	158.0	25.2					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 5 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
107	1156	Placebo	68.0	Female	CN	28.0	12.20
48.0	158.0	19.2					
	1157	Dula_0.75	58.0	Male	CN	24.0	3.70
67.0	166.0	24.3					
	1158	Dula_0.75	79.0	Male	CN	34.0	3.60
58.0	158.0	23.2					
	1159	Dula_0.75	49.0	Male	CN	9.0	4.50
65.0	158.0	26.0					
108	1160	Placebo	62.0	Female	FR	14.0	3.40
67.0	158.0	26.8					
	1161	Dula_1.5	53.0	Male	FR	21.0	9.10
87.0	156.0	35.7					
	1162	Placebo	40.0	Female	FR	37.0	13.00
80.0	158.0	32.0					
	1163	Placebo	63.0	Female	FR	35.0	7.10
57.0	158.0	22.8					
	1164	Placebo	35.0	Female	FR	33.0	11.60
71.0	158.0	28.4					
	1165	Dula_1.5	56.0	Male	FR	20.0	4.70
52.0	158.0	20.8					
	1166	Placebo	76.0	Female	FR	31.0	12.50
59.0	158.0	23.6					
	1167	Placebo	24.0	Female	FR	6.0	3.80
73.0	158.0	29.2					
	1168	Placebo	48.0	Female	FR	10.0	7.30
80.0	158.0	32.0					
	1169	Dula_1.5	60.0	Male	FR	9.0	6.90
105.0	164.0	39.0					
	1170	Dula_1.5	77.0	Male	FR	17.0	8.20
54.0	178.0	17.0					
	1171	Placebo	57.0	Female	FR	23.0	5.20
48.0	158.0	19.2					
	1172	Dula_1.5	72.0	Male	FR	16.0	12.20
78.0	158.0	31.2					
	1173	Placebo	18.0	Female	FR	7.0	2.30
48.0	158.0	19.2					
	1174	Dula_0.75	38.0	Female	FR	10.0	8.00
56.0	158.0	22.4					
	1176	Dula_1.5	64.0	Male	FR	22.0	4.20
99.0	182.0	29.9					
	1177	Dula_1.5	70.0	Male	FR	8.0	6.40
56.0	158.0	22.4					
	1178	Placebo	18.0	Female	FR	30.0	3.20
63.0	164.0	23.4					
	1179	Placebo	18.0	Female	FR	32.0	10.20
93.0	158.0	37.3					
	1180	Placebo	36.0	Female	FR	4.0	4.50
67.0	158.0	26.8					
	1181	Placebo	36.0	Female	FR	31.0	10.70
55.0	158.0	22.0					
	1182	Dula_0.75	83.0	Male	FR	12.0	6.60
49.0	158.0	19.6					
	1184	Dula_1.5	43.0	Male	FR	17.0	5.20
98.0	158.0	39.3					
	1185	Dula_0.75	45.0	Male	FR	24.0	5.80

52.0	158.0	20.8					
	1186	Placebo	78.0	Female	FR	35.0	5.30
86.0	158.0	34.4					
	1187	Dula_1.5	42.0	Male	FR	8.0	9.80
79.0	158.0	31.6					
	1188	Placebo	43.0	Female	FR	20.0	5.90
103.0	158.0	41.3					
	1189	Dula_1.5	67.0	Male	FR	24.0	7.90
79.0	181.0	24.1					
	1190	Dula_0.75	18.0	Female	FR	25.0	4.50
91.0	158.0	36.5					
	1191	Dula_1.5	46.0	Male	FR	5.0	12.40
55.0	175.0	18.0					
	1192	Dula_1.5	25.0	Male	FR	34.0	7.70
78.0	153.0	33.3					
	1193	Dula_0.75	77.0	Male	FR	28.0	6.50
49.0	182.0	14.8					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 6 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
108	1194	Dula_0.75	18.0	Female	FR	33.0	6.70
100.0	158.0	40.1					
48.0	158.0	Dula_0.75	73.0	Female	FR	26.0	3.80
61.0	158.0	19.2					
		Dula_1.5	52.0	Male	FR	7.0	2.80
94.0	158.0	24.4					
	1197	Placebo	38.0	Female	FR	14.0	11.10
95.0	182.0	28.4					
	1198	Dula_0.75	68.0	Female	FR	9.0	10.90
86.0	158.0	38.1					
	1199	Dula_0.75	18.0	Female	FR	6.0	2.50
48.0	158.0	34.4					
68.0	158.0	Dula_0.75	32.0	Male	FR	33.0	10.10
	1200	19.2					
	1201	Dula_0.75	48.0	Male	FR	7.0	2.80
64.0	158.0	27.2					
	1202	Dula_0.75	18.0	Female	FR	20.0	10.80
59.0	158.0	25.6					
	1203	Dula_0.75	53.0	Male	FR	23.0	10.60
67.0	151.0	23.6					
	1205	Dula_0.75	71.0	Male	FR	3.0	6.90
87.0	158.0	29.4					
	1206	Dula_1.5	76.0	Male	FR	30.0	4.20
53.0	158.0	34.9					
	1207	Placebo	58.0	Female	FR	15.0	.
100.0	158.0	21.2					
	1208	Dula_1.5	34.0	Male	FR	34.0	9.10
99.0	158.0	40.1					
	1210	Dula_1.5	62.0	Male	FR	20.0	10.70
60.0	158.0	39.7					
	1211	Dula_1.5	77.0	Male	FR	34.0	5.90
58.0	158.0	24.0					
	1212	Placebo	22.0	Female	FR	23.0	9.40
51.0	158.0	23.2					
	1213	Placebo	41.0	Female	FR	20.0	2.40
104.0	158.0	20.4					
	1214	Placebo	57.0	Female	FR	19.0	9.20
75.0	158.0	41.7					
	1215	Dula_1.5	47.0	Male	FR	13.0	3.60
105.0	158.0	30.0					
	1216	Dula_1.5	19.0	Male	FR	11.0	6.60
86.0	158.0	42.1					
	1217	Placebo	63.0	Female	FR	16.0	2.90
76.0	168.0	34.4					
	1218	Placebo	59.0	Female	FR	9.0	5.40
93.0	158.0	26.9					
	1219	Placebo	23.0	Female	FR	17.0	5.10
59.0	178.0	37.3					
	1220	Dula_0.75	18.0	Female	FR	31.0	7.20
86.0	161.0	18.6					
	1221	Dula_0.75	22.0	Male	FR	24.0	9.20
	1222	Dula_0.75	50.0	Male	FR	23.0	7.50
	158.0						
83.0	158.0	Dula_1.5	58.0	Male	FR	13.0	8.30
		33.2					

74.0	1224	Placebo	35.0	Female	FR	33.0	2.50
	154.0	31.2					
83.0	1225	Dula_1.5	28.0	Male	FR	26.0	3.20
	180.0	25.6					
59.0	1226	Dula_1.5	75.0	Male	FR	14.0	6.90
	157.0	23.9					
67.0	1227	Dula_0.75	60.0	Male	FR	20.0	9.60
	154.0	28.3					
62.0	1228	Dula_0.75	66.0	Male	FR	10.0	9.10
	154.0	26.1					
48.0	1229	Placebo	72.0	Female	FR	35.0	6.70
	154.0	20.2					
98.0	1230	Dula_0.75	50.0	Male	FR	28.0	11.80
	154.0	41.3					
90.0	1231	Dula_1.5	71.0	Male	FR	7.0	5.80
	166.0	32.7					
77.0	1232	Dula_1.5	55.0	Male	FR	28.0	7.10
	178.0	24.3					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 7 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age (Yrs)	Gender	Country)	Duration of	
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)				Diabetes (Yrs)	HbA1c (%)
108	1233	Placebo	73.0	Female	FR	34.0	6.30
89.0	154.0	37.5					
	1234	Dula_1.5	43.0	Male	FR	9.0	5.10
51.0	154.0	21.5					
	1235	Dula_1.5	43.0	Male	FR	4.0	8.10
52.0	154.0	21.9					
	1236	Dula_0.75	26.0	Male	FR	28.0	3.20
69.0	154.0	29.1					
	1237	Dula_0.75	52.0	Female	FR	8.0	7.10
95.0	179.0	29.6					
	1238	Dula_1.5	74.0	Male	FR	13.0	6.20
60.0	154.0	25.3					
	1239	Dula_1.5	53.0	Male	FR	32.0	6.70
46.0	154.0	19.4					
	1240	Dula_1.5	76.0	Male	FR	15.0	6.10
59.0	157.0	23.9					
	1241	Dula_1.5	65.0	Male	FR	18.0	10.50
83.0	154.0	35.0					
	1242	Dula_0.75	40.0	Male	FR	6.0	9.40
65.0	154.0	27.4					
	1243	Dula_1.5	60.0	Male	FR	37.0	7.20
45.0	174.0	14.9					
	1244	Placebo	24.0	Female	FR	27.0	8.90
68.0	154.0	28.7					
	1245	Dula_0.75	81.0	Male	FR	27.0	10.40
49.0	154.0	20.7					
	1246	Dula_0.75	56.0	Female	FR	34.0	5.70
87.0	154.0	36.7					
	1247	Placebo	30.0	Female	FR	13.0	12.00
102.0	154.0	43.0					
	1248	Dula_0.75	46.0	Male	FR	20.0	2.60
63.0	154.0	26.6					
	1249	Dula_0.75	65.0	Male	FR	14.0	.
54.0	154.0	22.8					
	1250	Placebo	51.0	Female	FR	12.0	4.90
69.0	154.0	29.1					
	1251	Placebo	55.0	Female	FR	22.0	.
79.0	154.0	33.3					
	1252	Dula_0.75	79.0	Male	FR	15.0	8.50
77.0	159.0	30.5					
	1253	Dula_1.5	68.0	Male	FR	15.0	4.10
65.0	154.0	27.4					
	1254	Dula_0.75	56.0	Male	FR	9.0	8.10
94.0	154.0	39.6					
	1257	Placebo	39.0	Female	FR	5.0	11.60
48.0	154.0	20.2					
	1258	Dula_1.5	27.0	Male	FR	7.0	3.00
70.0	154.0	29.5					
	1259	Dula_1.5	41.0	Male	FR	24.0	7.80
52.0	154.0	21.9					
	1260	Dula_1.5	50.0	Male	FR	13.0	3.10
55.0	154.0	23.2					
	1261	Dula_0.75	46.0	Male	FR	32.0	6.40
55.0	154.0	23.2					
	1262	Dula_0.75	18.0	Male	FR	11.0	9.40
46.0	154.0	19.4					

83.0	1263	Dula_0.75	21.0	Male	FR	36.0	4.10
	154.0	35.0					
	1264	Dula_1.5	75.0	Male	FR	10.0	4.00
93.0	154.0	39.2					
	1265	Placebo	26.0	Female	FR	13.0	10.70
49.0	154.0	20.7					
	1266	Dula_0.75	48.0	Male	FR	27.0	7.90
62.0	154.0	26.1					
	1267	Dula_0.75	40.0	Male	FR	36.0	4.00
53.0	154.0	22.3					
	1268	Dula_0.75	67.0	Female	FR	22.0	12.90
52.0	164.0	19.3					
	1269	Dula_0.75	66.0	Male	FR	38.0	7.40
104.0	154.0	43.9					
	1270	Dula_0.75	21.0	Male	FR	30.0	4.90
71.0	154.0	29.9					
	1271	Dula_1.5	83.0	Male	FR	4.0	9.00
88.0	154.0	37.1					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 8 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
108	1273	Dula_0.75	18.0	Male	FR	13.0	12.00
48.0	154.0	20.2					
	1274	Dula_0.75	47.0	Male	FR	16.0	10.20
67.0	154.0	28.3					
	1275	Placebo	30.0	Female	FR	29.0	11.90
73.0	154.0	30.8					
	1276	Placebo	34.0	Female	FR	23.0	8.70
101.0	174.0	33.4					
	1277	Dula_0.75	58.0	Female	FR	10.0	5.60
98.0	154.0	41.3					
	1278	Placebo	28.0	Female	FR	27.0	7.30
77.0	154.0	32.5					
	1279	Dula_0.75	31.0	Female	FR	13.0	3.70
94.0	154.0	39.6					
	1280	Dula_1.5	46.0	Male	FR	21.0	9.70
92.0	154.0	38.8					
	1281	Placebo	19.0	Female	FR	28.0	12.70
88.0	154.0	37.1					
	1282	Placebo	66.0	Female	FR	14.0	7.10
100.0	154.0	42.2					
	1283	Dula_0.75	41.0	Male	FR	31.0	3.50
101.0	154.0	42.6					
	1284	Dula_1.5	37.0	Male	FR	17.0	6.30
47.0	154.0	19.8					
	1285	Dula_0.75	68.0	Female	FR	11.0	7.30
84.0	154.0	35.4					
	1286	Dula_1.5	80.0	Male	FR	21.0	4.30
54.0	175.0	17.6					
	1287	Placebo	53.0	Female	FR	38.0	10.50
63.0	154.0	26.6					
	1288	Dula_1.5	19.0	Male	FR	24.0	11.30
70.0	175.0	22.9					
	1289	Dula_0.75	56.0	Male	FR	11.0	3.20
71.0	154.0	29.9					
	1290	Dula_1.5	21.0	Male	FR	21.0	5.90
88.0	154.0	37.1					
	1291	Placebo	40.0	Female	FR	35.0	6.50
55.0	179.0	17.2					
	1293	Dula_1.5	76.0	Male	FR	12.0	3.90
84.0	154.0	35.4					
	1294	Placebo	54.0	Female	FR	11.0	3.30
99.0	182.0	29.9					
	1295	Placebo	46.0	Female	FR	30.0	6.40
46.0	154.0	19.4					
	1296	Placebo	37.0	Female	FR	20.0	12.40
75.0	154.0	31.6					
	1297	Dula_0.75	74.0	Male	FR	16.0	10.00
71.0	154.0	29.9					
	1298	Dula_0.75	64.0	Female	FR	27.0	2.70
52.0	154.0	21.9					
	1299	Dula_1.5	18.0	Male	FR	28.0	8.80
68.0	154.0	28.7					
	1300	Placebo	70.0	Female	FR	37.0	2.20
52.0	154.0	21.9					
	1301	Dula_1.5	18.0	Male	FR	10.0	12.20
63.0	174.0	20.8					

77.0	1302	Placebo	38.0	Female	FR	15.0	12.90
	154.0	32.5					
70.0	1303	Dula_1.5	86.0	Male	FR	10.0	.
	154.0	29.5					
83.0	1304	Dula_0.75	72.0	Male	FR	32.0	4.90
	154.0	35.0					
93.0	1305	Placebo	72.0	Female	FR	22.0	3.80
	154.0	39.2					
66.0	1306	Placebo	60.0	Female	FR	10.0	9.00
	154.0	27.8					
53.0	1307	Placebo	76.0	Female	FR	22.0	11.70
	154.0	22.3					
66.0	1308	Dula_0.75	79.0	Male	FR	29.0	2.20
	178.0	20.8					
64.0	1309	Dula_1.5	84.0	Male	FR	25.0	2.20
	154.0	27.0					
89.0	1310	Dula_0.75	26.0	Female	FR	20.0	7.20
	154.0	37.5					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
 Page 9 of 16
 At Baseline
 17:15 22JAN2009
 Intent-to-treat patients

Body					Duration of		
Weight	Height	BMI	Age	Gender	Country)	Diabetes	HbA1c
Inv	Pat	Treatment	(Yrs)			(Yrs)	(%)
(Kg)	(cm)	(Kg/m2)					
108	1311	Placebo	23.0	Female	FR	10.0	9.20
54.0	162.0	20.6					
	1312	Dula_1.5	39.0	Male	FR	14.0	5.80
62.0	162.0	23.6					
	1313	Dula_0.75	26.0	Female	FR	24.0	10.20
81.0	174.0	26.8					
109	1314	Dula_1.5	18.0	Male	NZ	25.0	12.20
70.0	162.0	26.7					
	1315	Placebo	46.0	Female	NZ	7.0	11.10
61.0	162.0	23.2					
	1316	Dula_0.75	19.0	Male	NZ	37.0	11.60
72.0	162.0	27.4					
	1317	Dula_0.75	55.0	Male	NZ	14.0	12.40
97.0	162.0	37.0					
	1318	Dula_0.75	72.0	Male	NZ	20.0	8.90
48.0	162.0	18.3					
	1319	Dula_0.75	74.0	Female	NZ	10.0	5.50
76.0	162.0	29.0					
	1320	Dula_0.75	86.0	Male	NZ	29.0	9.70
67.0	162.0	25.5					
	1321	Dula_0.75	52.0	Male	NZ	24.0	3.10
46.0	162.0	17.5					
	1322	Dula_0.75	27.0	Male	NZ	20.0	12.80
90.0	162.0	34.3					
	1323	Dula_0.75	79.0	Male	NZ	6.0	10.20
52.0	162.0	19.8					
	1324	Placebo	53.0	Female	NZ	25.0	9.10
73.0	162.0	27.8					
	1325	Dula_0.75	61.0	Female	NZ	27.0	4.50
46.0	160.0	18.0					
	1326	Placebo	30.0	Female	NZ	18.0	3.80
79.0	162.0	30.1					
	1327	Dula_0.75	22.0	Female	NZ	30.0	10.10
65.0	162.0	24.8					
	1328	Dula_1.5	26.0	Male	NZ	37.0	7.90
65.0	162.0	24.8					
	1329	Dula_0.75	25.0	Female	NZ	24.0	7.00
79.0	162.0	30.1					
	1330	Placebo	18.0	Female	NZ	16.0	12.70
100.0	162.0	38.1					
	1331	Dula_0.75	49.0	Male	NZ	31.0	12.30
100.0	165.0	36.7					
	1332	Dula_1.5	48.0	Male	NZ	37.0	9.90
.	162.0						
	1333	Dula_1.5	37.0	Male	NZ	10.0	7.10
83.0	173.0	27.7					
	1334	Dula_0.75	38.0	Male	NZ	19.0	8.00
103.0	173.0	34.4					
	1335	Dula_1.5	75.0	Male	NZ	18.0	6.80
88.0	177.0	28.1					
	1336	Dula_0.75	70.0	Male	NZ	20.0	6.30
47.0	173.0	15.7					
	1338	Dula_1.5	48.0	Male	NZ	35.0	3.50
57.0	156.0	23.4					
	1339	Dula_1.5	86.0	Male	NZ	29.0	7.40

105.0	173.0	35.1					
	1340	Placebo	39.0	Female	NZ	11.0	9.70
52.0	173.0	17.4					
	1342	Dula_0.75	36.0	Female	NZ	7.0	5.60
78.0	173.0	26.1					
	1343	Placebo	40.0	Female	NZ	28.0	5.10
57.0	173.0	19.0					
	1344	Dula_1.5	86.0	Male	NZ	10.0	11.30
50.0	173.0	16.7					
	1345	Dula_0.75	55.0	Female	NZ	27.0	4.60
79.0	181.0	24.1					
	1347	Dula_0.75	83.0	Male	NZ	4.0	9.70
98.0	173.0	32.7					
	1348	Placebo	74.0	Female	NZ	6.0	3.10
69.0	179.0	21.5					
	1349	Dula_1.5	86.0	Male	NZ	27.0	8.30
46.0	173.0	15.4					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 10 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
109	1350	Dula_0.75	20.0	Female	NZ	6.0	4.00
96.0	173.0	32.1					
81.0	175.0	Dula_0.75	23.0	Male	NZ	34.0	3.40
	1352	Placebo	58.0	Female	NZ	17.0	9.20
56.0	173.0	18.7					
	1353	Placebo	18.0	Female	NZ	34.0	6.80
75.0	173.0	25.1					
	1354	Dula_1.5	48.0	Male	NZ	12.0	10.80
66.0	173.0	22.1					
	1355	Dula_0.75	61.0	Female	NZ	15.0	6.60
80.0	173.0	26.7					
	1356	Placebo	86.0	Female	NZ	16.0	6.00
56.0	173.0	18.7					
	1357	Dula_1.5	27.0	Male	NZ	31.0	4.10
83.0	151.0	36.4					
	1358	Dula_0.75	67.0	Male	NZ	16.0	10.30
72.0	173.0	24.1					
	1359	Dula_1.5	18.0	Male	NZ	38.0	.
86.0	173.0	28.7					
	1360	Dula_1.5	60.0	Male	NZ	25.0	11.50
60.0	173.0	20.0					
	1361	Placebo	53.0	Female	NZ	34.0	6.30
77.0	164.0	28.6					
	1362	Placebo	18.0	Female	NZ	18.0	5.00
83.0	173.0	27.7					
	1363	Dula_0.75	35.0	Male	NZ	12.0	10.40
77.0	173.0	25.7					
	1364	Dula_1.5	57.0	Male	NZ	27.0	7.40
99.0	173.0	33.1					
	1365	Dula_1.5	52.0	Male	NZ	31.0	3.10
69.0	173.0	23.1					
	1366	Dula_1.5	20.0	Male	NZ	29.0	7.30
78.0	173.0	26.1					
	1367	Placebo	38.0	Female	NZ	34.0	6.10
100.0	173.0	33.4					
	1368	Dula_1.5	69.0	Male	NZ	13.0	5.30
81.0	173.0	27.1					
	1369	Placebo	18.0	Female	NZ	10.0	2.30
71.0	173.0	23.7					
	1370	Placebo	34.0	Female	NZ	17.0	8.90
47.0	173.0	15.7					
	1371	Dula_1.5	73.0	Male	NZ	33.0	4.10
97.0	172.0	32.8					
	1372	Dula_1.5	23.0	Male	NZ	23.0	2.90
54.0	173.0	18.0					
	1373	Dula_1.5	49.0	Male	NZ	33.0	11.90
62.0	173.0	20.7					
	1374	Dula_0.75	50.0	Male	NZ	20.0	12.70
51.0	166.0	18.5					
	1375	Dula_0.75	75.0	Female	NZ	26.0	9.50
65.0	166.0	23.6					
	1376	Dula_0.75	71.0	Male	NZ	24.0	6.40
73.0	177.0	23.3					
	1377	Dula_0.75	22.0	Male	NZ	36.0	9.10
88.0	166.0	31.9					

	1378	Placebo	45.0	Female	NZ	21.0	3.50
79.0	166.0	28.7					
	1380	Dula_0.75	19.0	Male	NZ	36.0	5.40
74.0	166.0	26.9					
	1381	Dula_0.75	18.0	Male	NZ	3.0	3.60
78.0	166.0	28.3					
	1382	Dula_0.75	68.0	Male	NZ	8.0	5.40
48.0	166.0	17.4					
	1383	Dula_0.75	69.0	Male	NZ	35.0	12.50
97.0	166.0	35.2					
	1384	Dula_1.5	18.0	Male	NZ	31.0	11.00
95.0	173.0	31.7					
	1385	Dula_1.5	45.0	Male	NZ	36.0	8.70
73.0	166.0	26.5					
	1386	Dula_0.75	23.0	Male	NZ	23.0	6.90
89.0	166.0	32.3					
	1387	Dula_0.75	18.0	Male	NZ	10.0	4.80
48.0	177.0	15.3					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 11 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	Age (Yrs)	Gender	Country)	Duration of Diabetes (Yrs)	HbA1c (%)
109	1388	Dula_0.75	40.0	Female	NZ	15.0	9.10
69.0	166.0	25.0					
46.0	166.0	Dula_0.75	18.0	Male	NZ	30.0	9.40
	1390	Placebo	36.0	Female	NZ	6.0	10.70
52.0	166.0	18.9					
54.0	166.0	Dula_0.75	62.0	Male	NZ	37.0	8.20
	1392	Placebo	18.0	Female	NZ	10.0	6.00
52.0	166.0	18.9					
81.0	166.0	Dula_0.75	20.0	Male	NZ	37.0	8.70
	1393	29.4					
49.0	168.0	Dula_0.75	29.0	Male	NZ	29.0	6.40
	1394	17.4					
61.0	166.0	Dula_1.5	72.0	Male	NZ	33.0	5.40
	1395	22.1					
88.0	166.0	Dula_1.5	80.0	Male	NZ	31.0	4.00
	1396	31.9					
55.0	166.0	Placebo	30.0	Female	NZ	26.0	9.50
	1397	20.0					
75.0	151.0	Placebo	63.0	Female	NZ	28.0	13.00
	1398	32.9					
93.0	167.0	Placebo	85.0	Female	NZ	38.0	12.50
	1399	33.3					
46.0	166.0	Placebo	77.0	Female	NZ	5.0	10.30
	1400	16.7					
75.0	166.0	Dula_1.5	48.0	Male	NZ	27.0	9.30
	1401	27.2					
88.0	174.0	Dula_0.75	20.0	Male	NZ	30.0	13.00
	1402	29.1					
98.0	166.0	Dula_1.5	18.0	Male	NZ	38.0	6.20
	1403	35.6					
50.0	166.0	Dula_1.5	85.0	Male	NZ	6.0	12.90
	1404	18.1					
76.0	166.0	Dula_1.5	62.0	Male	NZ	12.0	8.10
	1405	27.6					
78.0	166.0	Placebo	19.0	Female	NZ	8.0	7.40
	1406	28.3					
68.0	159.0	Placebo	85.0	Female	NZ	16.0	10.90
	1407	26.9					
83.0	159.0	Dula_1.5	76.0	Male	NZ	15.0	12.60
	1408	32.8					
73.0	159.0	Dula_1.5	49.0	Male	NZ	10.0	7.90
	1409	28.9					
48.0	159.0	Dula_0.75	74.0	Female	NZ	26.0	10.40
	1410	19.0					
99.0	159.0	Placebo	29.0	Female	NZ	16.0	5.90
	1411	39.2					
46.0	159.0	Dula_1.5	37.0	Male	NZ	32.0	6.30
	1412	18.2					
102.0	159.0	Dula_1.5	58.0	Male	NZ	4.0	4.00
	1413	40.3					
85.0	159.0	Dula_0.75	39.0	Male	NZ	3.0	.
	1414	33.6					
86.0	159.0	Dula_1.5	60.0	Male	NZ	26.0	3.60
	1415	34.0					

66.0	1416	Dula_1.5	71.0	Male	NZ	9.0	4.70
159.0	1417	Placebo	80.0	Female	NZ	8.0	9.80
83.0	1418	Dula_0.75	85.0	Male	NZ	29.0	2.40
57.0	1419	Placebo	51.0	Female	NZ	32.0	2.60
49.0	1420	Dula_1.5	56.0	Male	NZ	29.0	2.50
94.0	1421	Placebo	18.0	Female	NZ	26.0	6.40
55.0	1422	Dula_1.5	82.0	Male	NZ	21.0	5.00
99.0	1423	Placebo	45.0	Female	NZ	33.0	3.10
97.0	1424	Dula_0.75	75.0	Male	NZ	16.0	7.20
82.0							

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 12 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	Age (Yrs)	Gender	Country)	Duration of Diabetes (Yrs)	HbA1c (%)
109	1425	Placebo	31.0	Female	NZ	9.0	10.30
99.0	157.0	40.2					
	1426	Dula_1.5	18.0	Male	NZ	10.0	11.30
82.0	159.0	32.4					
	1428	Placebo	24.0	Female	NZ	34.0	10.10
51.0	159.0	20.2					
	1429	Placebo	36.0	Female	NZ	33.0	6.20
85.0	159.0	33.6					
	1430	Dula_0.75	31.0	Female	NZ	9.0	10.60
86.0	159.0	34.0					
	1431	Dula_0.75	18.0	Male	NZ	5.0	6.90
52.0	159.0	20.6					
	1432	Dula_1.5	76.0	Male	NZ	10.0	12.40
83.0	159.0	32.8					
	1433	Placebo	31.0	Female	NZ	37.0	7.10
83.0	180.0	25.6					
	1434	Placebo	79.0	Female	NZ	18.0	2.60
57.0	159.0	22.5					
	1435	Placebo	37.0	Female	NZ	5.0	10.60
102.0	159.0	40.3					
	1436	Placebo	43.0	Female	NZ	16.0	4.50
49.0	181.0	15.0					
	1437	Placebo	83.0	Female	NZ	33.0	12.20
97.0	180.0	29.9					
	1438	Placebo	54.0	Female	NZ	31.0	11.30
79.0	159.0	31.2					
	1439	Dula_0.75	40.0	Male	NZ	36.0	6.60
56.0	159.0	22.2					
	1440	Placebo	39.0	Female	NZ	5.0	8.30
103.0	159.0	40.7					
	1441	Dula_0.75	18.0	Female	NZ	14.0	3.50
82.0	159.0	32.4					
	1443	Dula_0.75	45.0	Male	NZ	22.0	4.20
50.0	159.0	19.8					
	1444	Dula_1.5	59.0	Male	NZ	28.0	12.30
73.0	159.0	28.9					
	1445	Dula_1.5	52.0	Male	NZ	33.0	8.80
60.0	159.0	23.7					
	1446	Dula_1.5	18.0	Male	NZ	6.0	11.50
61.0	159.0	24.1					
	1447	Dula_1.5	72.0	Male	NZ	21.0	8.90
52.0	159.0	20.6					
	1448	Placebo	38.0	Female	NZ	27.0	2.30
68.0	159.0	26.9					
	1449	Dula_0.75	83.0	Male	NZ	5.0	8.20
46.0	159.0	18.2					
	1450	Placebo	71.0	Female	NZ	16.0	10.70
47.0	159.0	18.6					
	1451	Dula_0.75	45.0	Male	NZ	11.0	9.30
91.0	159.0	36.0					
	1452	Dula_1.5	35.0	Male	NZ	4.0	11.50
74.0	159.0	29.3					
	1453	Dula_1.5	37.0	Male	NZ	19.0	4.00
88.0	159.0	34.8					
	1454	Placebo	77.0	Female	NZ	20.0	3.10
100.0	159.0	39.6					

95.0	1455	Placebo	56.0	Female	NZ	11.0	7.90
	159.0	37.6					
64.0	1456	Dula_1.5	67.0	Male	NZ	4.0	9.20
	159.0	25.3					
50.0	1457	Dula_0.75	20.0	Female	NZ	35.0	5.50
	171.0	17.1					
58.0	1458	Placebo	57.0	Female	NZ	11.0	11.40
	159.0	22.9					
66.0	1459	Placebo	58.0	Female	NZ	12.0	4.30
	159.0	26.1					
59.0	1460	Dula_1.5	40.0	Male	NZ	15.0	10.40
	159.0	23.3					
53.0	1461	Placebo	18.0	Female	NZ	34.0	7.80
	159.0	21.0					
76.0	1463	Placebo	53.0	Female	NZ	29.0	6.80
	159.0	30.1					
51.0	1464	Dula_0.75	19.0	Male	NZ	5.0	8.80
	159.0	20.2					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 13 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
109	1465	Dula_0.75	58.0	Male	NZ	24.0	6.80
61.0	159.0	24.1					
	1466	Dula_0.75	85.0	Male	NZ	28.0	5.60
88.0	159.0	34.8					
	1467	Placebo	34.0	Female	NZ	15.0	3.90
77.0	174.0	25.4					
	1468	Dula_0.75	22.0	Male	NZ	5.0	4.40
52.0	159.0	20.6					
	1469	Dula_1.5	23.0	Male	NZ	23.0	5.70
58.0	159.0	22.9					
	1470	Dula_0.75	68.0	Male	NZ	19.0	4.40
55.0	159.0	21.8					
	1471	Dula_0.75	65.0	Male	NZ	16.0	4.80
54.0	159.0	21.4					
	1472	Dula_1.5	18.0	Male	NZ	28.0	8.40
93.0	159.0	36.8					
	1473	Dula_1.5	66.0	Male	NZ	7.0	12.40
98.0	170.0	33.9					
	1474	Dula_0.75	36.0	Female	NZ	30.0	3.40
56.0	159.0	22.2					
	1475	Dula_1.5	35.0	Male	NZ	35.0	8.50
78.0	159.0	30.9					
	1476	Placebo	72.0	Female	NZ	24.0	7.00
57.0	159.0	22.5					
	1478	Placebo	25.0	Female	NZ	22.0	5.10
99.0	159.0	39.2					
	1479	Dula_0.75	54.0	Male	NZ	4.0	3.10
105.0	159.0	41.5					
	1480	Dula_0.75	18.0	Male	NZ	35.0	6.70
97.0	159.0	38.4					
	1481	Dula_1.5	52.0	Male	NZ	15.0	11.00
98.0	159.0	38.8					
	1482	Placebo	20.0	Female	NZ	8.0	12.90
52.0	173.0	17.4					
	1483	Dula_1.5	53.0	Male	NZ	6.0	7.30
75.0	180.0	23.1					
	1484	Dula_0.75	35.0	Male	NZ	9.0	2.80
90.0	159.0	35.6					
	1485	Dula_1.5	79.0	Male	NZ	5.0	6.60
93.0	159.0	36.8					
	1486	Dula_0.75	18.0	Male	NZ	8.0	3.70
51.0	159.0	20.2					
	1487	Dula_1.5	27.0	Male	NZ	14.0	2.20
76.0	159.0	30.1					
	1488	Dula_0.75	54.0	Male	NZ	34.0	4.50
74.0	159.0	29.3					
	1489	Dula_0.75	18.0	Male	NZ	20.0	6.30
83.0	159.0	32.8					
	1490	Placebo	18.0	Female	NZ	10.0	6.00
62.0	159.0	24.5					
	1491	Dula_1.5	70.0	Male	NZ	9.0	5.00
92.0	159.0	36.4					
	1492	Dula_0.75	38.0	Male	NZ	4.0	10.20
47.0	159.0	18.6					
	1493	Placebo	46.0	Female	NZ	35.0	3.50
69.0	159.0	27.3					

62.0	1494	Dula_0.75	40.0	Male	NZ	4.0	6.30
	159.0	24.5					
91.0	1495	Dula_1.5	57.0	Male	NZ	23.0	9.40
	152.0	39.4					
50.0	1496	Dula_0.75	69.0	Female	NZ	5.0	6.70
	159.0	19.8					
87.0	1497	Placebo	70.0	Female	NZ	35.0	4.10
	159.0	34.4					
88.0	1498	Dula_0.75	58.0	Male	NZ	14.0	5.30
	159.0	34.8					
65.0	1499	Dula_1.5	28.0	Male	NZ	12.0	10.20
	159.0	25.7					
85.0	1500	Dula_1.5	83.0	Male	NZ	26.0	10.40
	159.0	33.6					
81.0	1501	Placebo	20.0	Female	NZ	31.0	10.50
	159.0	32.0					
45.0	1502	Placebo	63.0	Female	NZ	14.0	7.30
	159.0	17.8					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 14 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age (Yrs)	Gender	Country)	Duration of	
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)				Diabetes (Yrs)	HbA1c (%)
109	1503	Dula_0.75	49.0	Male	NZ	29.0	2.90
104.0	159.0	41.1					
53.0	1504	Dula_0.75	70.0	Male	NZ	32.0	2.50
	159.0	21.0					
102.0	1505	Dula_0.75	20.0	Female	NZ	19.0	9.30
	159.0	40.3					
99.0	1506	Placebo	67.0	Female	NZ	28.0	3.60
	159.0	39.2					
77.0	1507	Dula_1.5	47.0	Male	NZ	26.0	11.30
	159.0	30.5					
54.0	1508	Placebo	24.0	Female	NZ	18.0	3.60
	175.0	17.6					
83.0	1509	Dula_1.5	57.0	Male	NZ	34.0	8.50
	159.0	32.8					
51.0	1510	Dula_1.5	18.0	Male	NZ	38.0	12.10
	159.0	20.2					
66.0	1511	Dula_1.5	53.0	Male	NZ	19.0	11.80
	159.0	26.1					
94.0	1512	Dula_1.5	58.0	Male	NZ	7.0	6.00
	159.0	37.2					
98.0	1513	Dula_1.5	43.0	Male	NZ	35.0	8.40
	159.0	38.8					
100.0	1514	Placebo	79.0	Female	NZ	12.0	9.40
	159.0	39.6					
93.0	1515	Dula_0.75	41.0	Male	NZ	31.0	6.90
	159.0	36.8					
60.0	1516	Dula_0.75	81.0	Male	NZ	38.0	4.80
	159.0	23.7					
100.0	1517	Dula_0.75	54.0	Female	NZ	21.0	6.60
	159.0	39.6					
68.0	1518	Placebo	52.0	Female	NZ	26.0	11.50
	158.0	27.2					
55.0	1519	Dula_0.75	75.0	Male	NZ	19.0	4.20
	168.0	19.5					
92.0	1520	Dula_0.75	60.0	Female	NZ	37.0	9.50
	159.0	36.4					
70.0	1521	Placebo	23.0	Female	NZ	14.0	8.40
	159.0	27.7					
69.0	1522	Dula_0.75	75.0	Male	NZ	31.0	12.50
	159.0	27.3					
89.0	1523	Dula_1.5	47.0	Male	NZ	18.0	12.00
	159.0	35.2					
81.0	1524	Placebo	82.0	Female	NZ	3.0	4.00
	159.0	32.0					
64.0	1525	Placebo	46.0	Female	NZ	19.0	3.60
	159.0	25.3					
99.0	1526	Dula_0.75	26.0	Male	NZ	16.0	5.10
	159.0	39.2					
99.0	1527	Placebo	85.0	Female	NZ	30.0	10.50
	159.0	39.2					
56.0	1528	Dula_1.5	78.0	Male	NZ	28.0	11.80
	159.0	22.2					
61.0	1529	Placebo	22.0	Female	NZ	18.0	12.60
	159.0	24.1					
93.0	1530	Dula_0.75	81.0	Male	NZ	8.0	6.90
	159.0	36.8					

83.0	1531	Placebo	86.0	Female	NZ	5.0	4.80
102.0	1532	Dula_0.75	31.0	Female	NZ	7.0	5.30
84.0	1533	Placebo	69.0	Female	NZ	22.0	8.10
53.0	1534	Dula_0.75	27.0	Male	NZ	33.0	10.40
91.0	1535	Dula_0.75	18.0	Male	NZ	21.0	10.40
89.0	1537	Dula_0.75	54.0	Male	NZ	24.0	4.70
78.0	1538	Dula_0.75	62.0	Male	NZ	23.0	7.20
46.0	1539	Dula_1.5	51.0	Male	NZ	27.0	4.10
78.0	1540	Dula_0.75	40.0	Female	NZ	35.0	5.00

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page 15 of 16
At Baseline
17:15 22JAN2009
Intent-to-treat patients

Body			Age	Gender	Country)	Duration of	HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m2)	(Yrs)			Diabetes (Yrs)	(%)
109	1541	Dula_1.5	18.0	Male	NZ	14.0	11.80
51.0	159.0	20.2					
	1542	Dula_1.5	43.0	Male	NZ	37.0	4.90
78.0	159.0	30.9					
	1543	Dula_0.75	66.0	Female	NZ	33.0	11.00
49.0	159.0	19.4					
	1544	Dula_1.5	83.0	Male	NZ	13.0	9.90
102.0	159.0	40.3					
	1545	Dula_1.5	48.0	Male	NZ	17.0	10.60
100.0	166.0	36.3					
	1546	Dula_0.75	46.0	Male	NZ	13.0	8.90
85.0	159.0	33.6					
	1547	Placebo	50.0	Female	NZ	6.0	11.60
48.0	159.0	19.0					
	1548	Dula_0.75	51.0	Male	NZ	32.0	11.10
66.0	159.0	26.1					
	1549	Placebo	62.0	Female	NZ	15.0	7.80
75.0	158.0	30.0					
	1550	Placebo	29.0	Female	NZ	11.0	3.90
102.0	159.0	40.3					
	1551	Dula_1.5	32.0	Male	NZ	10.0	10.00
102.0	159.0	40.3					
	1552	Dula_0.75	84.0	Female	NZ	29.0	10.10
100.0	159.0	39.6					
	1553	Dula_0.75	72.0	Male	NZ	27.0	5.60
53.0	159.0	21.0					
	1554	Placebo	36.0	Female	NZ	10.0	3.80
97.0	159.0	38.4					
	1555	Dula_0.75	30.0	Male	NZ	16.0	10.40
60.0	159.0	23.7					
	1556	Dula_0.75	18.0	Male	NZ	28.0	9.20
87.0	159.0	34.4					
	1557	Dula_0.75	85.0	Male	NZ	24.0	2.30
45.0	151.0	19.7					
	1558	Dula_1.5	68.0	Male	NZ	34.0	6.10
82.0	159.0	32.4					
	1559	Dula_1.5	74.0	Male	NZ	36.0	9.10
70.0	159.0	27.7					
	1560	Dula_1.5	18.0	Male	NZ	5.0	9.20
48.0	152.0	20.8					
	1561	Placebo	60.0	Female	NZ	33.0	3.40
96.0	159.0	38.0					
	1562	Dula_0.75	40.0	Male	NZ	5.0	4.10
55.0	159.0	21.8					
	1563	Dula_1.5	23.0	Male	NZ	20.0	7.50
92.0	159.0	36.4					
	1564	Dula_0.75	22.0	Female	NZ	15.0	10.10
51.0	159.0	20.2					
	1565	Placebo	77.0	Female	NZ	19.0	6.70
74.0	159.0	29.3					
	1566	Dula_0.75	83.0	Male	NZ	13.0	10.50
64.0	152.0	27.7					
	1567	Dula_1.5	18.0	Male	NZ	13.0	2.40
90.0	159.0	35.6					
	1568	Dula_0.75	28.0	Male	NZ	8.0	9.30
95.0	159.0	37.6					

84.0	1569	Placebo	58.0	Female	NZ	4.0	2.70
	159.0	33.2					
56.0	1570	Dula_1.5	60.0	Male	NZ	19.0	8.00
	159.0	22.2					
97.0	1571	Dula_0.75	30.0	Female	NZ	24.0	7.20
	159.0	38.4					
67.0	1572	Dula_1.5	26.0	Male	NZ	30.0	11.50
	159.0	26.5					
49.0	1573	Dula_1.5	45.0	Male	NZ	38.0	9.40
	159.0	19.4					
105.0	1574	Dula_0.75	59.0	Male	NZ	34.0	3.70
	159.0	41.5					
90.0	1575	Dula_1.5	54.0	Male	NZ	8.0	8.90
	159.0	35.6					
101.0	1576	Dula_1.5	63.0	Male	NZ	31.0	7.30
	159.0	40.0					
51.0	1577	Placebo	31.0	Female	NZ	17.0	12.20
	159.0	20.2					

Listing of patient Demographics, Characteristics, and Cardiovascular Risks
 Page 16 of 16
 At Baseline
 17:15 22JAN2009
 Intent-to-treat patients

Body			Age		Duration of		HbA1c
Weight Inv (Kg)	Height Pat (cm)	BMI Treatent (Kg/m ²)	(Yrs)	Gender	Country)	(Yrs)	(%)
109 93.0	1578 159.0	Dula_1.5 36.8	61.0	Male	NZ	14.0	4.90
110 83.0	1579 159.0	Dula_1.5 32.8	73.0	Male	CH	10.0	8.50
92.0	1580 159.0	Dula_1.5 36.4	38.0	Male	CH	13.0	7.30
56.0	1581 159.0	Dula_1.5 22.2	86.0	Male	CH	24.0	7.60
71.0	1582 159.0	Dula_0.75 28.1	21.0	Male	CH	6.0	8.20
86.0	1583 159.0	Placebo 34.0	78.0	Female	CH	4.0	2.40
95.0	1584 159.0	Placebo 37.6	66.0	Female	CH	35.0	5.70
98.0	1585 159.0	Placebo 38.8	47.0	Female	CH	29.0	8.20
102.0	1586 159.0	Dula_1.5 40.3	75.0	Male	CH	3.0	3.20
60.0	1587 159.0	Dula_0.75 23.7	77.0	Male	CH	35.0	2.20
53.0	1588 159.0	Dula_1.5 21.0	60.0	Male	CH	34.0	7.30
76.0	1589 159.0	Dula_1.5 30.1	34.0	Male	CH	5.0	10.50
89.0	1590 159.0	Dula_0.75 35.2	72.0	Male	CH	30.0	7.80
77.0	1591 159.0	Placebo 30.5	31.0	Female	CH	30.0	6.80
111 64.0	1593 165.0	Placebo 23.5	62.0	Female	CH	13.0	6.00
58.0	1594 159.0	Placebo 22.9	54.0	Female	CH	22.0	7.80
63.0	1595 161.0	Dula_0.75 24.3	37.0	Male	CH	16.0	2.90
82.0	1596 161.0	Placebo 31.6	30.0	Female	CH	25.0	11.60
50.0	1597 161.0	Dula_1.5 19.3	46.0	Male	CH	13.0	10.00
62.0	1598 161.0	Dula_1.5 23.9	79.0	Male	CH	15.0	12.90
90.0	1599 171.0	Dula_1.5 30.8	52.0	Male	CH	8.0	12.50
92.0	1600 161.0	Dula_1.5 35.5	55.0	Male	CH	22.0	2.30

Abbreviations: BMI = body mass index; DBP = Diastolic blood pressure; bpm = beats per minute; SBP = systolic blood pressure; cm = centimeter; inv = investigator; kg = kilogram; kg/m² = kilogram per square meter; mmHg = millimeter of mercury; Pat = patient; PIs = pulse rate; Yrs = years.

Here is The Program For That

```
%let prgnm = lsbsca1;
```

```
options nocenter nodate nonumber mprint mlogic ps = 46 ls = 133 formchar = "|----|+|---  
+|=|<>*" charcode;
```

```
%include "C:\Users\Desktop\SAS_ADS\LUMS\out2rtf.sas";
```

```
libname db "C:\Users\Desktop\SAS_ADS\ADS";
```

```
libname out "C:\Users\Desktop\ADI\TFL_OUTPUT";
```

```
%let outfile = C:\Users\Desktop\ADI\TFL_OUTPUT;
```

```
proc format;
```

```
value $ gen 'F' = 'Female' 'M' = 'Male';
```

```
run;
```

```
%macro lsbsca1 (rptnm = , pop = );
```

```
proc printto new log = "C:\Users\Desktop\ADI\SYSTEM_FILES\&prgnm..log";
```

```
run;
```

```
%put ----- Start of lsbsca1 macro -----;
```

```
****getting information from subjinfo Ads****;
```

```
proc sort data = db.subjinfo out = subjinfo;
```



```
by invid subjid;  
where &pop. = 1;  
run;
```

```
****getting information from labs Ads****;
```

```
proc sort data = db.labs out = labs;  
by invid subjid visid;  
where lbtestcd = "K48" and visid in (1, 2) and not missing(lbrn);  
run;
```

```
data labs_base (keep = invid subjid lbrn);  
set labs;  
by invid subjid visid;  
if last.subjid;  
run;
```

```
****getting information from vitals Ads****;
```

```
proc sort data = db.vitals out = vitals;  
by invid subjid visid;  
where vstestcd = upcase("WGT") and visid in (1, 2) and not missing(vsrn);  
run;
```

```
data vitals_base (keep = invid subjid vsrn);  
set vitals;  
by invid subjid visid;  
if last.subjid;  
run;
```

```
data comb;
merge subjinfo (in = a)    labs_base vitals_base;
by invid subjid;
if a;
if not missing(height) then hgt_m = height/100;
if not missing(vsrn) and not missing(hgt_m) then bmi = put((vsrn/(hgt_m*hgt_m)), 5.1);
run;
```

```
data final;
    set comb;
    by invid subjid;
    length c1-c11 $20;
```

```
c1 = put(invid, 4.);
c2 = put(subjid, 4.);
c3 = strip(trt);
c4 = put(ageyr, 5.1);
c5 = put(sex, $gen.);
c6 = put(country, 4.);
c7 = put(diabdur_rnyr, 5.1);
c8 = put(lbrn, 6.2);
c9 = put(vsrn, 6.1);
c10 = put(height, 6.1);
c11 = put(bmi, 5.1);
```

```
pbrk = 1;
run;
```

```
*** Creating dataset for validation ***;
data out.&rptnm. (keep = c1 - c11);
  set final;
run;

*** Creating required output rtf file ***;
ods listing close;

options pageno = 1;

filename tmpfile temp;

proc printto new print = tmpfile;
run;

ods listing;

title;
footnote;

proc report data = final headline nowd missing split = '^';
  columns pbrk c1 - c11;

  define pbrk / group order = data noprint;
  define c1 / group order = data 'Inv' width=12 spacing =0 center ;
  define c2 / display 'Pat' width = 12 spacing = 0 center;
  define c3 / display "Treatent" width = 12 spacing = 0 center;
  define c4 / display "Age^(Yrs)" width = 12 spacing = 0 center;
  define c5 / display "Gender" width = 12 spacing = 0 center;
```

```
define c6 / display "Country)" width = 12 spacing = 0 center;
define c7 / display "Duration of^Diabetes^(Yrs)" width = 12 spacing = 0 center;
define c8 / display "HbA1c^(%)" width = 12 spacing = 0 center;
define c9 / display "Body^Weight^(Kg)" width = 12 spacing = 0 center;
define c10 / display "Height^(cm)" width = 12 spacing = 0 center;
define c11 / display "BMI^(Kg/m2)" width = 13 spacing = 0 center;
```

```
break after c1 / skip;
```

```
%if %upcase(&rptnm.) = LSBSCA11 %then %let tit3 = Intent-to-treat patients;
%else %if %upcase(&rptnm.) = LSBSCA12 %then %let tit3 = Per protocol patients;
```

```
compute before _page_;
```

```
line @1 "Listing of patient Demographics, Characteristics, and Cardiovascular Risks
Page_X__of_Y__";
```

```
line @1 "At Baseline
&systeme. &sysdate9.";
```

```
line @1 "&tit3";
```

```
line @1 " ";
```

```
line @1 133*'-!';
```

```
endcomp;
```

```
compute after pbrk;
```

```
line @1 133*'-!';
```

```
line @1 "Abbreviations: BMI = body mass index; DBP = Diastolic blood pressure; bpm
= beats per minute; SBP = systolic blood pressure; ";
```

```
line @1 "cm = centimeter; inv = investigator;kg = kilogram; kg/m2 = kilogram per
```

```
square meter; mmHg = millimeter of mercury; ";
  line @1 "Pat = patient; PLs = pulse rate; Yrs = years. ";
endcomp;
run;

proc printto print = print log = log;
run;

%out2rtf (in = tmpfile, out = &outfile.\&rptnm..rtf, orient = l, center = );

filename tmpfile clear;

%put ----- End of lsbsca1 macro -----;

%mend lsbsca1;

%lsbsca1 (rptnm = lsbsca11, pop = subjitt);
%lsbsca1 (rptnm = lsbsca12, pop = subjpps);
```